PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Mebeverine→

Mebeverine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
3625-06-7
Molecular formula
C25H35NO5
Molecular weight
429.5 g/mol
Drug class
Musculotropic gastrointestinal antispasmodic
Mechanism of action
Acts directly on gastrointestinal smooth muscle without materially affecting normal gut motility. The exact mechanism is not fully known; proposed contributing actions include altered ion-channel permeability, noradrenaline reuptake inhibition, local anaesthetic activity and weak antimuscarinic/phosphodiesterase effects.
Indications / reported uses
  • Symptomatic treatment of irritable bowel syndrome
  • Other functional bowel conditions associated with colicky abdominal pain, cramps, spastic constipation, diarrhoea and flatulence, according to product information

Sources: UK SmPC — Mebeverine 135 mg tablets (updated 9 Apr 2026) · UK SmPC — Mebeverine MR 200 mg capsules · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Mebeverine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Mebeverine Permitted Daily Exposure (PDE) report (the Mebeverine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Mebeverine Occupational Exposure Limit (OEL) report (the Mebeverine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.